This pharmacokinetic characteristic is critical because it can effectively block mTORC1 and two and PI3K signal transduction in tumour tissues (VS-5584 with mTOR and PI3Kα activities of 37 and 16 nM, respectively). The gene discussed is PIK3CA; the disease is neoplasm.